Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 98

1.

Trastuzumab-related cardiotoxicity in early breast cancer: a cohort study.

Bonifazi M, Franchi M, Rossi M, Moja L, Zambelli A, Zambon A, Corrao G, La Vecchia C, Zocchetti C, Negri E.

Oncologist. 2013;18(7):795-801. doi: 10.1634/theoncologist.2013-0065. Epub 2013 Jul 3.

PMID:
23823908
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Factors predicting trastuzumab-related cardiotoxicity in a real-world population of women with HER2+ breast cancer.

Naumann D, Rusius V, Margiotta C, Nevill A, Carmichael A, Rea D, Sintler M.

Anticancer Res. 2013 Apr;33(4):1717-20.

PMID:
23564821
[PubMed - indexed for MEDLINE]
3.

Trastuzumab-related cardiotoxicity among older patients with breast cancer.

Chavez-MacGregor M, Zhang N, Buchholz TA, Zhang Y, Niu J, Elting L, Smith BD, Hortobagyi GN, Giordano SH.

J Clin Oncol. 2013 Nov 20;31(33):4222-8. doi: 10.1200/JCO.2013.48.7884. Epub 2013 Oct 14.

PMID:
24127446
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Cardiac safety of trastuzumab as adjuvant treatment for Japanese patients with early breast cancer.

Ishihara M, Mukai H, Nagai S, Mukohara T.

Int J Clin Oncol. 2009 Oct;14(5):431-5. doi: 10.1007/s10147-009-0898-z. Epub 2009 Oct 25.

PMID:
19856052
[PubMed - indexed for MEDLINE]
5.

Trastuzumab-related cardiac events in the treatment of early breast cancer.

Fried G, Regev T, Moskovitz M.

Breast Cancer Res Treat. 2013 Nov;142(1):1-7. doi: 10.1007/s10549-013-2732-6. Epub 2013 Oct 24.

PMID:
24154507
[PubMed - indexed for MEDLINE]
6.

High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study.

Onitilo AA, Engel JM, Stankowski RV, Liang H, Berg RL, Doi SA.

Breast Cancer Res Treat. 2012 Jul;134(1):291-8. doi: 10.1007/s10549-012-2039-z. Epub 2012 Apr 4.

PMID:
22476854
[PubMed - indexed for MEDLINE]
7.

Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility.

Telli ML, Hunt SA, Carlson RW, Guardino AE.

J Clin Oncol. 2007 Aug 10;25(23):3525-33. Review.

PMID:
17687157
[PubMed - indexed for MEDLINE]
8.

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD; Herceptin Adjuvant (HERA) Trial Study Team.

N Engl J Med. 2005 Oct 20;353(16):1659-72.

PMID:
16236737
[PubMed - indexed for MEDLINE]
Free Article
9.

Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors.

Farolfi A, Melegari E, Aquilina M, Scarpi E, Ibrahim T, Maltoni R, Sarti S, Cecconetto L, Pietri E, Ferrario C, Fedeli A, Faedi M, Nanni O, Frassineti GL, Amadori D, Rocca A.

Heart. 2013 May;99(9):634-9. doi: 10.1136/heartjnl-2012-303151. Epub 2013 Jan 24.

PMID:
23349345
[PubMed - indexed for MEDLINE]
10.

Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer.

Tarantini L, Cioffi G, Gori S, Tuccia F, Boccardi L, Bovelli D, Lestuzzi C, Maurea N, Oliva S, Russo G, Faggiano P; Italian Cardio-Oncologic Network.

J Card Fail. 2012 Feb;18(2):113-9. doi: 10.1016/j.cardfail.2011.10.015. Epub 2011 Dec 3.

PMID:
22300778
[PubMed - indexed for MEDLINE]
11.

Trastuzumab therapy in Australia: which patients with HER2+ metastatic breast cancer are assessed for cardiac function?

Lu CY, Srasuebkul P, Drew AK, Chen K, Ward RL, Pearson SA.

Breast. 2013 Aug;22(4):482-7. doi: 10.1016/j.breast.2013.04.011. Epub 2013 May 9.

PMID:
23664254
[PubMed - indexed for MEDLINE]
12.

Trastuzumab containing regimens for early breast cancer.

Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, Guarneri V, D'Amico R.

Cochrane Database Syst Rev. 2012 Apr 18;4:CD006243. doi: 10.1002/14651858.CD006243.pub2. Review.

PMID:
22513938
[PubMed - indexed for MEDLINE]
13.

Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study.

Bowles EJ, Wellman R, Feigelson HS, Onitilo AA, Freedman AN, Delate T, Allen LA, Nekhlyudov L, Goddard KA, Davis RL, Habel LA, Yood MU, McCarty C, Magid DJ, Wagner EH; Pharmacovigilance Study Team.

J Natl Cancer Inst. 2012 Sep 5;104(17):1293-305. doi: 10.1093/jnci/djs317.

PMID:
22949432
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J, Kaufmann M, Cameron D, Bell R, Bergh J, Coleman R, Wardley A, Harbeck N, Lopez RI, Mallmann P, Gelmon K, Wilcken N, Wist E, Sánchez Rovira P, Piccart-Gebhart MJ; HERA study team.

Lancet. 2007 Jan 6;369(9555):29-36.

PMID:
17208639
[PubMed - indexed for MEDLINE]
15.

Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors.

Serrano C, Cortés J, De Mattos-Arruda L, Bellet M, Gómez P, Saura C, Pérez J, Vidal M, Muñoz-Couselo E, Carreras MJ, Sánchez-Ollé G, Tabernero J, Baselga J, Di Cosimo S.

Ann Oncol. 2012 Apr;23(4):897-902. doi: 10.1093/annonc/mdr348. Epub 2011 Aug 9.

PMID:
21828361
[PubMed - indexed for MEDLINE]
Free Article
16.

Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab.

Ky B, Putt M, Sawaya H, French B, Januzzi JL Jr, Sebag IA, Plana JC, Cohen V, Banchs J, Carver JR, Wiegers SE, Martin RP, Picard MH, Gerszten RE, Halpern EF, Passeri J, Kuter I, Scherrer-Crosbie M.

J Am Coll Cardiol. 2014 Mar 4;63(8):809-16. doi: 10.1016/j.jacc.2013.10.061. Epub 2013 Nov 27.

PMID:
24291281
[PubMed - indexed for MEDLINE]
17.

Baseline diastolic dysfunction as a predictive factor of trastuzumab-mediated cardiotoxicity after adjuvant anthracycline therapy in breast cancer.

Cochet A, Quilichini G, Dygai-Cochet I, Touzery C, Toubeau M, Berriolo-Riedinger A, Coudert B, Cottin Y, Fumoleau P, Brunotte F.

Breast Cancer Res Treat. 2011 Dec;130(3):845-54. doi: 10.1007/s10549-011-1714-9. Epub 2011 Sep 15.

PMID:
21918836
[PubMed - indexed for MEDLINE]
18.

Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.

Burstein HJ, Harris LN, Marcom PK, Lambert-Falls R, Havlin K, Overmoyer B, Friedlander RJ Jr, Gargiulo J, Strenger R, Vogel CL, Ryan PD, Ellis MJ, Nunes RA, Bunnell CA, Campos SM, Hallor M, Gelman R, Winer EP.

J Clin Oncol. 2003 Aug 1;21(15):2889-95.

PMID:
12885806
[PubMed - indexed for MEDLINE]
19.

Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies.

Pinto AC, Ades F, de Azambuja E, Piccart-Gebhart M.

Breast. 2013 Aug;22 Suppl 2:S152-5. doi: 10.1016/j.breast.2013.07.029. Review.

PMID:
24074778
[PubMed - indexed for MEDLINE]
20.

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM; CLEOPATRA Study Group.

N Engl J Med. 2012 Jan 12;366(2):109-19. doi: 10.1056/NEJMoa1113216. Epub 2011 Dec 7.

PMID:
22149875
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk